Dr. Erika Hamilton, M.D
NPI: 1902007107
Total Payments
$310,629
2024 Payments
$88,283
Companies
64
Transactions
529
Medicare Patients
6,085
Medicare Billing
$996,133
Payment Breakdown by Category
Research$152,219 (49.0%)
Consulting$82,343 (26.5%)
Other$33,884 (10.9%)
Travel$32,232 (10.4%)
Food & Beverage$9,921 (3.2%)
Education$30.93 (0.0%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $152,219 | 80 | 49.0% |
| Consulting Fee | $82,343 | 38 | 26.5% |
| Travel and Lodging | $32,232 | 24 | 10.4% |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $29,084 | 18 | 9.4% |
| Food and Beverage | $9,921 | 365 | 3.2% |
| Honoraria | $4,800 | 2 | 1.5% |
| Education | $30.93 | 2 | 0.0% |
Payments by Type
General
$158,410
449 transactions
Research
$152,219
80 transactions
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Daiichi Sankyo Company LTD | $72,063 | 55 | $0 (2024) |
| MacroGenics, Inc. | $65,261 | 5 | $0 (2021) |
| PFIZER INC. | $59,847 | 82 | $0 (2024) |
| Eli Lilly and Company | $27,913 | 41 | $0 (2024) |
| F. Hoffmann-La Roche AG | $27,321 | 27 | $0 (2024) |
| Seagen Inc. | $11,129 | 16 | $0 (2023) |
| Novartis Pharmaceuticals Corporation | $9,588 | 29 | $0 (2024) |
| Puma Biotechnology, Inc. | $6,375 | 8 | $0 (2018) |
| Stemline Therapeutics Inc. | $5,222 | 7 | $0 (2024) |
| Gilead Sciences, Inc. | $4,673 | 14 | $0 (2024) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $88,283 | 107 | Daiichi Sankyo Company LTD ($49,991) |
| 2023 | $30,528 | 99 | PFIZER INC. ($21,936) |
| 2022 | $22,163 | 55 | Daiichi Sankyo Inc. ($11,636) |
| 2021 | $85,161 | 29 | MacroGenics, Inc. ($65,261) |
| 2020 | $26,682 | 50 | F. Hoffmann-La Roche AG ($8,245) |
| 2019 | $24,619 | 87 | Eli Lilly and Company ($12,340) |
| 2018 | $23,628 | 66 | Eli Lilly and Company ($10,279) |
| 2017 | $9,566 | 36 | Genentech USA, Inc. ($4,085) |
All Payment Transactions
529 individual payment records from CMS Open Payments — Page 1 of 22
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/31/2024 | F. Hoffmann-La Roche AG | — | — | In-kind items and services | $1,794.83 | Research |
| Study: Ph I Dose escalation w GDC 0077 in breast cancer | ||||||
| 12/31/2024 | F. Hoffmann-La Roche AG | — | — | In-kind items and services | $1,377.29 | Research |
| Study: Ph I Dose escalation w GDC 0077 in breast cancer | ||||||
| 12/23/2024 | Genmab U.S., Inc. | Epkinly (Drug) | Food and Beverage | In-kind items and services | $24.25 | General |
| Category: Oncology | ||||||
| 12/23/2024 | BeiGene USA, Inc. | BRUKINSA (Drug) | Food and Beverage | In-kind items and services | $16.52 | General |
| Category: Oncology | ||||||
| 12/14/2024 | Gilead Sciences, Inc. | Trodelvy (Drug) | Food and Beverage | In-kind items and services | $108.38 | General |
| Category: ONC | ||||||
| 12/14/2024 | Gilead Sciences, Inc. | Trodelvy (Drug) | Food and Beverage | In-kind items and services | $28.82 | General |
| Category: ONC | ||||||
| 12/12/2024 | Daiichi Sankyo Inc. | Enhertu (Drug) | Food and Beverage | In-kind items and services | $27.68 | General |
| Category: ONCOLOGY | ||||||
| 12/10/2024 | AstraZeneca UK Limited | — | Food and Beverage | In-kind items and services | $30.00 | General |
| 11/26/2024 | Novartis Pharmaceuticals Corporation | — | Consulting Fee | Cash or cash equivalent | $675.00 | General |
| 11/25/2024 | Bayer Healthcare Pharmaceuticals Inc. | Nubeqa (Drug), Stivarga, Vitrakvi | Food and Beverage | In-kind items and services | $13.36 | General |
| Category: Oncology | ||||||
| 11/22/2024 | Eisai Inc. | Lenvima (Drug) | Food and Beverage | In-kind items and services | $21.69 | General |
| Category: Oncology | ||||||
| 11/20/2024 | Genentech USA, Inc. | Itovebi (Biological), Perjeta, Phesgo | Food and Beverage | In-kind items and services | $16.88 | General |
| Category: BioOncology | ||||||
| 11/19/2024 | SUN PHARMACEUTICAL INDUSTRIES INC. | Odomzo (Drug), YONSA | Food and Beverage | In-kind items and services | $18.65 | General |
| Category: Oncology | ||||||
| 11/13/2024 | Lilly USA, LLC | VERZENIO (Drug), RETEVMO, JAYPIRCA | Food and Beverage | In-kind items and services | $25.77 | General |
| Category: Oncology | ||||||
| 11/11/2024 | Merck Sharp & Dohme LLC | KEYTRUDA (Biological), LYNPARZA | Food and Beverage | In-kind items and services | $31.99 | General |
| Category: ONCOLOGY | ||||||
| 10/30/2024 | Daiichi Sankyo Inc. | Enhertu (Drug) | Food and Beverage | In-kind items and services | $26.73 | General |
| Category: ONCOLOGY | ||||||
| 10/29/2024 | Stemline Therapeutics Inc. | ELZONRIS (Drug) | Food and Beverage | In-kind items and services | $25.51 | General |
| Category: Oncology | ||||||
| 10/28/2024 | AstraZeneca Pharmaceuticals LP | IMFINZI (Biological) | Food and Beverage | In-kind items and services | $22.70 | General |
| Category: Oncology | ||||||
| 10/12/2024 | Blueprint Medicines Corporation | AYVAKIT (Drug) | Food and Beverage | Cash or cash equivalent | $32.01 | General |
| Category: Oncology / Rare Diseases | ||||||
| 10/09/2024 | Coherus Biosciences Inc. | Udenyca (Biological) | Food and Beverage | In-kind items and services | $15.06 | General |
| Category: Granulocyte colony stimulating factor | ||||||
| 10/08/2024 | Regeneron Healthcare Solutions, Inc. | LIBTAYO (Biological) | Food and Beverage | In-kind items and services | $23.11 | General |
| Category: ONCOLOGY | ||||||
| 10/07/2024 | Tempus AI, Inc | — | Food and Beverage | In-kind items and services | $29.56 | General |
| 10/03/2024 | Eli Lilly and Company | — | Consulting Fee | Cash or cash equivalent | $600.00 | General |
| 09/30/2024 | Daiichi Sankyo Inc. | Vanflyta (Drug) | Food and Beverage | In-kind items and services | $23.02 | General |
| Category: ONCOLOGY | ||||||
| 09/24/2024 | EMD Serono, Inc. | — | Food and Beverage | Cash or cash equivalent | $21.13 | General |
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| A STUDY OF MGD013 IN PATIENTS WITH UNRESECTABLE OR METASTATIC NEOPLASMS | MacroGenics, Inc. | $65,261 | 5 |
| A RANDOMIZED, OPEN-LABEL, PHASE 3 STUDY OF ABEMACICLIB COMBINED WITH STANDARD ADJUVANT ENDOCRINE THERAPY VERSUS STANDARD ADJUVANT ENDOCRINE THERAPY ALONE IN PATIENTS WITH HIGH RISK, NODE POSITIVE, EARLY STAGE, HORMONE RECEPTOR POSITIVE, HUMAN EPIDERMAL RECEPTOR 2 NEGATIVE, BREAST CANCER | Eli Lilly and Company | $14,691 | 4 |
| PHASE 12A DOSE ESCALATION AND EXPANSION STUDY EVALUATING SAFETY TOLERABILITY PHARMACOKINETIC PHARMACODYNAMICS AND ANTITUMOR ACTIVITY OF PF06873600 AS A SINGLE AGENT AND IN COMBINATION WITH ENDOCRINE THERAPY | PFIZER INC. | $13,867 | 10 |
| A PHASE 2 STUDY OF PREXASERTIB IN PLATINUM-RESISTANT OR REFRACTORY RECURRENT OVARIAN CANCER | Eli Lilly and Company | $7,479 | 2 |
| Ph I Dose escalation w GDC 0077 in breast cancer | F. Hoffmann-La Roche AG | $6,707 | 6 |
| COFETUZUMAB PELIDOTIN CLINICAL PUBLICATION PROGRAM | PFIZER INC. | $6,400 | 2 |
| PALBOCICLIB CLINICAL PUBLICATION PROGRAM | PFIZER INC. | $6,070 | 6 |
| ONCOLOGY PORTFOLIO CLINICAL PUBLICATION PROGRAM | PFIZER INC. | $4,470 | 3 |
| CLEE011O12301C | Novartis Pharmaceuticals Corporation | $3,563 | 1 |
| PF06647263 CLINICAL PUBLICATION PROGRAM | PFIZER INC. | $3,530 | 2 |
| A PHASE 1/2 STUDY OF REGN4018 (A MUC16XCD3 BISPECIFIC ANTIBODY) ADMINISTERED ALONE OR IN COMBINATION WITH CEMIPLIMAB IN PATIENTS WITH RECURRENT OVARIAN CANCER | Regeneron Pharmaceuticals, Inc. | $3,507 | 14 |
| Phase Ib Combo for HER2 BC with Herceptin Kadcyla Perjeta aPDL1 | F. Hoffmann-La Roche AG | $3,099 | 1 |
| An Open-Label Phase I Dose Escalation Study Evaluating the Safety, Tolerability, and Pharmacokinetics of GDC-0077 Administered Alone and in Combination with Endocrine and Targeted Therapies in Patients with Locally Advanced or Metastatic Hormone Receptor-Positive Breast Cancer | F. Hoffmann-La Roche AG | $2,332 | 7 |
| PF06804103 MAVELERTINIB PF4136309 PF06952229 NIROGACESTAT PF06671008 ARRY 382 PF04691502 PF06821497 PF06939999 PF06840003 PF07265807 COFETUZUMAB PELIDOTIN MULTI PRODUCT UTOMILUMAB GEDATOLISIB ELRANATAMAB PF067535 CLINICAL PUBLICATION PROGRAM | PFIZER INC. | $1,880 | 2 |
| A PHASE IB, OPEN-LABEL STUDY EVALUATING THE SAFETY AND PHARMACOKINETICS OF ATEZOLIZUMAB ANTI-PD-L1 ANTIBODY IN COMBINATION WITH TRASTUZUMAB EMTANSINE OR WITH TRASTUZUMAB AND PERTUZUMAB WITH AND WITHOUT DOCETAXEL IN PATIENTS WITH HER2-POSITIVE BREAST CANCER AND ATEZOLIZUMAB WITH DOXORUBICIN AND CYCLOPHOSPHAMIDE IN HER2-NEGATIVE BREAST CANCER | F. Hoffmann-La Roche AG | $1,573 | 2 |
| RESEARCH RELATED PUBLICATIONS SUPPORT | Novartis Pharmaceuticals Corporation | $1,500 | 1 |
| GEDATOLISIB PF06840003 PF04691502 PF06939999 PF06650808 ELRANATAMAB PF06952229 PF06821497 PF07265807 PF06804103 TRASTUZUMAB PFIZER PF06664178 PF06940434 NIROGACESTAT PF06671008 TINLORAFENIB PF06753512 MAVELERTI CLINICAL PUBLICATION PROGRAM | PFIZER INC. | $1,400 | 1 |
| POSTMONARCH: A RANDOMIZED, DOUBLE BLIND, PLACEBO-CONTROLLED, PHASE 3 STUDY TO COMPARE THE EFFICACY OF ABEMACICLIB PLUS FULVESTRANT TO PLACEBO PLUS FULVESTRANT IN PARTICIPANTS WITH HR+, HER2-, ADVANCED OR METASTATIC BREAST CANCER FOLLOWING PROGRESSION ON A CDK4 & 6 INHIBITOR AND ENDOCRINE THERAPY | Eli Lilly and Company | $1,394 | 1 |
| HEOR - LEE011-2016-PLS | Novartis Pharmaceuticals Corporation | $1,037 | 1 |
| ELRANATAMAB CLINICAL PUBLICATION PROGRAM | PFIZER INC. | $660.00 | 2 |
| Uptake of atezolizumab treatment and PD-L1 testing in metastatic triple negative breast cancer 12-months following accelerated approval in the United States | F. Hoffmann-La Roche AG | $657.78 | 1 |
| A PHASE 1A/1B STUDY OF LY3484356 ADMINISTERED AS MONOTHERAPY AND IN COMBINATION WITH ABEMACICLIB TO PATIENTS WITH ER+, HER2- LOCALLY ADVANCED OR METASTATIC BREAST CANCER | Eli Lilly and Company | $450.00 | 2 |
| TUKYSA CLINICAL PUBLICATION PROGRAM | PFIZER INC. | $330.00 | 1 |
| A PHASE 1A/1B STUDY OF LY3484356 ADMINISTERED AS MONOTHERAPY AND IN COMBINATION WITH ABEMACICLIB TO PATIENTS WITH ER+ HER2- LOCALLY ADVANCED OR METASTATIC BREAST CANCER | Eli Lilly and Company | $300.00 | 1 |
| EMONARCHER: A RANDOMIZED, DOUBLE BLIND, PLACEBO-CONTROLLED PHASE 3 STUDY OF ABEMACICLIB PLUS STANDARD ADJUVANT ENDOCRINE THERAPY IN PARTICIPANTS WITH HIGH-RISK, NODE-POSITIVE, HR+, HER2+ EARLY BREAST CANCER WHO HAVE COMPLETED ADJUVANT HER2-TARGETED THERAPY | Eli Lilly and Company | $61.00 | 1 |
| EMBER-2: A PHASE 1, OPEN-LABEL, PREOPERATIVE WINDOW STUDY EVALUATING THE BIOLOGICAL EFFECTS OF LY3484356 IN POST-MENOPAUSAL WOMEN WITH STAGE I-III ESTROGEN RECEPTOR-POSITIVE, HER2-NEGATIVE BREAST CANCER | Eli Lilly and Company | $1.01 | 1 |
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 32 | 1,076 | 7,149 | $384,834 | $157,742 |
| 2022 | 39 | 1,567 | 31,425 | $619,648 | $266,779 |
| 2021 | 44 | 1,948 | 42,862 | $802,185 | $373,551 |
| 2020 | 36 | 1,494 | 11,572 | $499,953 | $198,062 |
Total Patients
6,085
Total Services
93,008
Medicare Billing
$996,133
Procedure Codes
151
All Medicare Procedures & Services
151 procedure records from CMS Medicare Utilization — Page 1 of 7
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2023 | 124 | 390 | $110,415 | $49,800 | 45.1% |
| J0897 | Injection, denosumab, 1 mg | Office | 2023 | 11 | 2,340 | $73,380 | $43,549 | 59.3% |
| 96413 | Administration of chemotherapy into vein, 1 hour or less | Office | 2023 | 46 | 243 | $92,680 | $22,115 | 23.9% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 53 | 82 | $16,368 | $7,261 | 44.4% |
| 80053 | Blood test, comprehensive group of blood chemicals | Office | 2023 | 118 | 680 | $12,240 | $7,038 | 57.5% |
| 85025 | Complete blood cell count (red cells, white blood cell, platelets), automated test and automated differential white blood cell count | Office | 2023 | 119 | 742 | $10,388 | $5,647 | 54.4% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Office | 2023 | 19 | 19 | $6,498 | $2,876 | 44.3% |
| 36415 | Insertion of needle into vein for collection of blood sample | Office | 2023 | 82 | 330 | $4,955 | $2,772 | 55.9% |
| 96375 | Injection of additional new drug or substance into vein | Office | 2023 | 19 | 197 | $12,965 | $2,122 | 16.4% |
| 86300 | Immunologic analysis for detection of tumor antigen, quantitative; ca 15-3 | Office | 2023 | 25 | 78 | $2,808 | $1,590 | 56.6% |
| 96372 | Injection of drug or substance under skin or into muscle | Office | 2023 | 31 | 132 | $8,922 | $1,347 | 15.1% |
| 96415 | Administration of chemotherapy into vein, each additional hour | Office | 2023 | 17 | 54 | $4,555 | $1,096 | 24.1% |
| 86304 | Immunologic analysis for detection of tumor antigen, quantitative; ca 125 | Office | 2023 | 14 | 52 | $1,872 | $1,060 | 56.6% |
| 96365 | Infusion into a vein for therapy, prevention, or diagnosis, 1 hour or less | Office | 2023 | 14 | 24 | $4,678 | $1,002 | 21.4% |
| 96367 | Infusion into a vein for therapy, prevention, or diagnosis, additional sequential infusion, 1 hour or less | Office | 2023 | 18 | 49 | $4,232 | $959.60 | 22.7% |
| 83615 | Lactate dehydrogenase (enzyme) level | Office | 2023 | 24 | 153 | $1,683 | $905.76 | 53.8% |
| 82728 | Ferritin (blood protein) level | Office | 2023 | 32 | 53 | $1,272 | $708.08 | 55.7% |
| 82668 | Erythropoietin (protein) level | Office | 2023 | 25 | 37 | $1,184 | $681.17 | 57.5% |
| 82746 | Folic acid level, serum | Office | 2023 | 27 | 42 | $1,050 | $605.22 | 57.6% |
| 82607 | Cyanocobalamin (vitamin b-12) level | Office | 2023 | 26 | 40 | $1,040 | $591.20 | 56.8% |
| 84100 | Phosphate level | Office | 2023 | 22 | 123 | $1,107 | $571.95 | 51.7% |
| 96360 | Infusion into a vein for hydration, 31-60 minutes | Office | 2023 | 15 | 22 | $3,586 | $515.24 | 14.4% |
| 82248 | Bilirubin level, direct | Office | 2023 | 14 | 101 | $909.00 | $496.92 | 54.7% |
| 84550 | Uric acid level, blood | Office | 2023 | 19 | 108 | $864.00 | $478.44 | 55.4% |
| 96361 | Infusion into a vein for hydration, each additional hour | Office | 2023 | 16 | 47 | $1,786 | $431.52 | 24.2% |
About Dr. Erika Hamilton, M.D
Dr. Erika Hamilton, M.D is a Student in an Organized Health Care Education/Training Program healthcare provider based in Nashville, Tennessee. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 05/29/2007. The National Provider Identifier (NPI) number assigned to this provider is 1902007107.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Erika Hamilton, M.D has received a total of $310,629 in payments from pharmaceutical and medical device companies, with $88,283 received in 2024. These payments were reported across 529 transactions from 64 companies. The most common payment nature is "" ($152,219).
As a Medicare-enrolled provider, Hamilton has provided services to 6,085 Medicare beneficiaries, totaling 93,008 services with total Medicare billing of $996,133. Data is available for 4 years (2020–2023), covering 151 distinct procedure/service records.
Ad
Practice Information
- Specialty Student in an Organized Health Care Education/Training Program
- Other Specialties Internal Medicine, Hematology & Oncology
- Location Nashville, TN
- Active Since 05/29/2007
- Last Updated 08/19/2013
- Taxonomy Code 390200000X
- Entity Type Individual
- NPI Number 1902007107
Products in Payments
- Enhertu (Drug) $50,667
- TECENTRIQ (Biological) $10,634
- IBRANCE (Drug) $7,042
- Nerlynx (Drug) $6,375
- KISQALI (Drug) $6,220
- TUKYSA (Drug) $5,323
- Non-Covered Product (Drug) $4,488
- ELREXFIO (Drug) $3,940
- Perjeta (Biological) $3,939
- Kadcyla (Biological) $3,924
- Tecentriq (Biological) $3,790
- ENHERTU (Drug) $3,347
- LIBTAYO (Biological) $3,085
- KEYTRUDA (Biological) $2,817
- PIQRAY (Drug) $2,400
- Orserdu (Drug) $2,077
- Lenvima (Drug) $270.20
- Trodelvy (Drug) $268.05
- VERZENIO (Drug) $248.49
- OPDIVO (Biological) $187.38
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Student in an Organized Health Care Education/Training Program Doctors in Nashville
Wade Iams, Md, MD
Student in an Organized Health Care Education/Training Program — Payments: $269,547
Student in an Organized Health Care Education/Training Program $269,547
Dr. Francesca Bagnato, M.d, M.D
Student in an Organized Health Care Education/Training Program — Payments: $136,578
Student in an Organized Health Care Education/Training Program $136,578
Toluwalashe Onamusi, Md, MD
Student in an Organized Health Care Education/Training Program — Payments: $80,030
Student in an Organized Health Care Education/Training Program $80,030
Dr. Dario Englot, M.d., Ph.d, M.D., PH.D
Student in an Organized Health Care Education/Training Program — Payments: $51,636
Student in an Organized Health Care Education/Training Program $51,636
Dr. Avni Finn, Md, Mba, MD, MBA
Student in an Organized Health Care Education/Training Program — Payments: $47,165
Student in an Organized Health Care Education/Training Program $47,165
Dhyanesh Patel, M.d, M.D
Student in an Organized Health Care Education/Training Program — Payments: $40,812
Student in an Organized Health Care Education/Training Program $40,812